Bioinformatics of the Brain

Masrori and P. van Damme, “Amyotrophic lateral sclerosis: a clinical

view,” European Journal of Neurology, vol. 27, pp. 1918–1929, 2020.

Kacem, I. Sghaier, S. Bougatef, et al., “Epidemiological and clinical

atures of amyotrophic lateral sclerosis in a tunisian cohort,” Amy-

rophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 21,

p. 131–139, 2019.

. E. Cudkowicz, S. Titus, M. Kearney, et al., “Safety and efficacy of

ftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised,

uble-blind, placebo-controlled trial,” The Lancet Neurology, vol. 13,

p. 1083–1091, 2014.

Xu, R. D. Henderson, M. David, et al., “Neurofilaments as biomark-

s for amyotrophic lateral sclerosis: A systematic review and meta-

alysis,” PLoS ONE, vol. 11, 2016.

Hartzfeld, N. Siddique, D. E. Victorson, et al., “Reproductive

cision-making among individuals at risk for familial amyotrophic lat-

al sclerosis,” Amyotrophic Lateral Sclerosis and Frontotemporal De-

neration, vol. 16, pp. 114–119, 2015.

. R. O’brien, “Management of patients with motor neurone disease,”

11.

C. Wijesekera and P. N. Leigh, “Amyotrophic lateral sclerosis,” Or-

anet Journal of Rare Diseases, vol. 4, pp. 3–3, 2009.

Radunović, H. Mitsumoto, and N. P. Leigh, “Clinical care of pa-

ents with amyotrophic lateral sclerosis,” The Lancet Neurology, vol. 6,

p. 913–925, 2007.

D. Michael Swash, “Motor neuron disease: Classification and nomen-

ature,” Amyotrophic Lateral Sclerosis and Other Motor Neuron Dis-

ders, vol. 1, pp. 105–112, 2000.

Al-Chalabi, O. Hardiman, M. C. Kiernan, et al., “Amyotrophic lat-

al sclerosis: moving towards a new classification system,” The Lancet

eurology, vol. 15, pp. 1182–1194, 2016.

G. Miller, J.D., Mitchell, M. Lyon, D.H. Moore, Riluzole for

myotrophic

lateral

sclerosis

(ALS)/motor

neuron

disease

MND).

Cochrane

Database

Syst

Rev.

2002;(2):CD001447.

doi:

.1002/14651858.CD001447.

-M. Park, S.-Y. Kim, D. Park, and J.-S. Park, “Effect of edaravone

erapy in Korean amyotrophic lateral sclerosis (als) patients,” Neuro-

gical Sciences, vol. 41, pp. 119–123, 2019.